



Center for
Healthcare
Innovation

Webinar: How the Prevalence of Chronic Diseases Impacts Clinical Research

WEBINAR SUMMARY

Tuesday, March 3, 2022 | 11 AM - 12 PM CST

Access the webinar: <https://www.chisite.org/how-the-prevalence-of-chronic-diseases-impacts-clinical-research>

This webinar focuses on chronic medical conditions in underrepresented groups and how these conditions impact clinical trial participation. Specifically focusing on kidney diseases, the discussion will center around eligibility criteria, safety, and dialogue with patients from underrepresented communities. One study found that a "lack of diversity in clinical trials is a moral, scientific, and medical issue. When trial participants are homogenous (e.g., primarily one gender, race/ethnicity, or age group), findings may be skewed and result in a body of clinical knowledge that is not generalizable". New NIH data shows "35% of African Americans suffer from kidney failure and Hispanics have experienced a 70% increase in kidney failure cases since 2000".

Furthermore, African Americans are "10 times more likely to develop kidney failure related to hypertension, and 3 times more likely to progress to kidney failure than Caucasians". In a study through the American Journal of Nephrology, in 3,000 chronic kidney disease-related clinical trials, only 34 were directed toward African Americans. With African Americans comprising 13.2% of the US population and having an elevated risk, this number is exceptionally low (4). This webinar brings together industry experts to discuss the impact of chronic conditions on clinical trial enrollment in underrepresented groups and solutions to address barriers in trial participation related to chronic diseases through patient communication, revised eligibility criteria, and community engagement.

African Americans are

10x more likely to develop kidney failure related to hypertension

3x more likely to progress to kidney failure than Caucasians

Source: Kidney Disease Health Disparities

Hispanics have experienced

70%
increase in kidney failure cases since

2000

Source: National Institutes of Health (NIH)

●●● WEBINAR PANELISTS ●●●



**Moderator: Dr. Neelum
Aggarwal, MD**

Chief Diversity Officer,
American Medical Women's Association



Dr. Monica Parker, MD

Assistant Professor of Medicine, Department
of Neurology,
Emory Alzheimer's Disease Research Center



Dr. Jeff Sherman, MD, FACP

Chief Medical Officer,
Horizon Therapeutics



- When recruiting patients for clinical trials, adequate leadtime must be allocated to allow for any potential challenges or hurdles in patient recruitment.
- Understand how to best convey to patients and their families by remembering that a clinical trial is a new opportunity to receive a new treatment that could help with a serious medical condition.
- Ensure high-quality continuity of care for the patients and their families regardless of whether they are able to participate in the clinical trial.
- Develop culturally competent approaches to communicating the risks and benefits of clinical trials that consider lower trust in medical racism impacting communities of color in the US.

